8-K: GlycoMimetics Announces Positive Phase 3 Trial Results for Uproleselan in Primary Refractory AML

GlycoMimetics' Phase 3 trial of uproleselan shows a significant improvement in overall survival for patients with primary refractory acute myeloid leukemia.

Summary

• GlycoMimetics announced comprehensive results from its pivotal Phase 3 clinical trial of uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML).
• The study randomized 388 patients across nine countries, comparing uproleselan plus chemotherapy to chemotherapy alone.
• The primary endpoint of overall survival (OS) in the intent-to-treat (ITT) population was not statistically significant, with a median OS of 13.0 months for the uproleselan arm versus 12.3 months for the placebo arm.
• However, a significant improvement in median overall survival (mOS) was observed in the primary refractory AML subgroup, with 31.2 months for the uproleselan arm compared to 10.1 months for the placebo arm.
• The median duration of response (DoR) for complete remission (CR) was not reached for primary refractory patients in the uproleselan arm, compared to 12.7 months for the placebo arm.
• Adverse events were consistent with the known safety profiles of the chemotherapy regimens used in the study.
• The company is advancing discussions with the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology for a Phase 2/3 study of uproleselan with chemotherapy in older adults with frontline AML.

Sentiment

Score: 7

Explanation: The document presents positive results for a specific subgroup of patients (primary refractory AML), which is a significant development. However, the overall study did not meet its primary endpoint, which tempers the enthusiasm. The company's plans to engage with regulators and the NCI are also positive.

Positives

• Uproleselan demonstrated a clinically meaningful improvement in median overall survival (mOS) for patients with primary refractory AML, with 31.2 months compared to 10.1 months for the placebo arm.
• The median duration of response (DoR) for complete remission (CR) was not reached for primary refractory patients in the uproleselan arm, compared to 12.7 months for the placebo arm.
• Patients who received a hematopoietic stem cell transplant (HSCT) after study treatment in the uproleselan arm had a median overall survival that was not reached.
• The safety profile of uproleselan was consistent with the known side effects of the chemotherapy regimens used in the study.
• There is a potential regulatory pathway for uproleselan in certain AML patients, particularly those with primary refractory disease.

Negatives

• The primary endpoint of overall survival (OS) in the intent-to-treat (ITT) population was not statistically significant.
• For early relapse patients, the median overall survival (mOS) was 3.7 months in the uproleselan arm compared to 6.4 months in the placebo arm.
• For late relapse patients, the median overall survival (mOS) was 15.4 months in the uproleselan arm compared to 18.2 months in the placebo arm.
• The overall complete remission (CR) rate at the end of induction was 36.1% in the uproleselan arm compared to 33.5% in the placebo arm, which was not statistically significant.

Risks

• The overall survival benefit was not statistically significant in the entire study population.
• The benefit of uproleselan was not observed in early or late relapse AML patients.
• The company needs to successfully navigate regulatory pathways to gain approval for uproleselan.
• The company is dependent on the success of ongoing clinical trials and partnerships.
• There are risks associated with the development and commercialization of new drugs, including unexpected safety or efficacy data.

Future Outlook

GlycoMimetics is exploring a potential regulatory pathway for uproleselan, particularly in the primary refractory AML population, and is advancing discussions with the NCI for a Phase 2/3 study in frontline AML. The company is also seeking a partnership for its SCD program.

Management Comments

• Daniel DeAngelo, M.D., Ph.D., stated that the data helps understand how prespecified stratification factors impacted survival outcomes.
• Harout Semerjian, Chief Executive Officer of GlycoMimetics, said that uproleselan may offer clinically meaningful patient benefit in multiple settings, including primary refractory AML.
• Harout Semerjian also stated that the company is committed to addressing unmet needs of AML patients and plans to engage with regulators and NCI to discuss potential paths forward for uproleselan.

Industry Context

The results are significant in the context of AML treatment, where there is a high unmet need for effective therapies, particularly for patients with primary refractory disease. The positive results in this subgroup could position uproleselan as a valuable treatment option.

Comparison to Industry Standards

• The median overall survival of 10.1 months in the placebo arm for primary refractory AML is consistent with the poor prognosis typically seen in this patient population.
• The 31.2 months median overall survival in the uproleselan arm for primary refractory AML is a significant improvement compared to standard treatments.
• The study's results are particularly notable when compared to historical data for relapsed/refractory AML, where 5-year survival rates are only around 10%.
• The company is also exploring a potential regulatory pathway for uproleselan in certain AML patients, such as the primary refractory population, which is a significant step forward.

Stakeholder Impact

• Shareholders may react positively to the promising results in the primary refractory AML subgroup.
• Patients with primary refractory AML may benefit from a new treatment option.
• Employees of GlycoMimetics may be encouraged by the progress of uproleselan.
• The company's partners and collaborators may be interested in the potential of uproleselan.

Next Steps

• GlycoMimetics plans to engage with regulators to discuss potential paths forward for uproleselan.
• The company will continue discussions with the NCI and the Alliance for Clinical Trials in Oncology for a Phase 2/3 study of uproleselan in frontline AML.
• The company is seeking a partnership for its SCD program.

Key Dates

Keywords

uproleselan, acute myeloid leukemia, AML, relapsed/refractory, primary refractory, overall survival, clinical trial, cancer, hematopoietic stem cell transplant, chemotherapy